Study design of the CLOSURE i trial: A prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale

Stroke

Volumn 41, Issue 12, 2010, Pages 2872-2883

  Furlan, Anthony J ^a   Reisman, Mark ^b   Massaro, Joseph ^c   Mauri, Laura ^c   Adams, Harold ^d   Albers, Gregory W ^e   Felberg, Robert ^f   Herrmann, Howard ^g   Kar, Saibal ^h   Landzberg, Michael ⁱ   Raizner, Albert ^j   Wechsler, Lawrence ^k  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f GEISINGER MEDICAL CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j HOUSTON METHODIST HOSPITAL   (United States)

^k UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

atrial septal closure; cryptogenic stroke; patent foramen ovale; percutaneous closure; right to left shunt

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CLOPIDOGREL; HEPARIN; WARFARIN;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; CARDIOVASCULAR EQUIPMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TRANSIENT ISCHEMIC ATTACK;

BLOOD COAGULATION DISORDERS; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ENDPOINT DETERMINATION; FOLLOW-UP STUDIES; FORAMEN OVALE, PATENT; HUMANS; INTRACRANIAL EMBOLISM; ISCHEMIC ATTACK, TRANSIENT; LABORATORY TECHNIQUES AND PROCEDURES; MIGRAINE DISORDERS; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RESEARCH DESIGN; SAMPLE SIZE; STENTS; STROKE;

EID: 78650417539     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.593376     Document Type: Article

References (45)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y, for the American Heart Association Statistics C, Stroke Statistics S. Heart disease and stroke statistics, 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
2. Steiner MM, Di Tullio MR, Rundek T, Gan R, Chen X, Liguori C, Brainin M, Homma S, Sacco RL. Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke. 1998;29:944-948.
3. Hart RG, Miller VT. Cerebral infarction in young adults: a practical approach. Stroke. 1983;14:110-114.
4. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382-390.
5. DeCastro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM, Beccia M, Colonnese C, Fedele F, Fieschi C, Pandian NG. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke. 2000;31:2407-2413.
6. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J. 1995;130: 1083-1088.
7. Bogousslavsky J, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology. 1996;46:1301-1305.
8. Cabanes L, Mas JL, Cohen A, Amarenco P, Cabanes PA, Oubary P, Chedru F, Guérin F, Bousser MG, de Recondo J. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age: a study using transesophageal echocardiogra-phy. Stroke. 1993;24:1865-1873.
9. Comess KA, Beach KW, Lytle NJ, Golby AJ, Albers GW. Transesoph-ageal echocardiography and carotid ultrasound in patients with cerebral ischemia: prevalence of findings and recurrent stroke risk. J Am Coll Cardiol. 1994;23:1598-1603.
10. Di Tullio M, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117:461-465.
11. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, for the PFOiCSSI. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625-2631.
12. Lechat P, Lascault G, Mas JL. Prevalence of patent foramen ovale in young patients with ischemic cerebral complications. Arch Mal Coeur Vaiss. 1989;82:847-852.
13. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740-1746.
14. Nendaz MR, Junod AF, Bogousslavsky J. Preventing stroke recurrence in patients with patent foramen ovale: antithrombotic therapy, foramen closure, or therapeutic abstention? a decision analytic perspective. Am Heart J. 1998;135:532-541.
15. Webster MWCA, Smith HJ, Swift DL, Sharpe DN, Bass NM, Glasgow GL. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11-12.
16. Hagen PT, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17-20.
17. Jones Jr. HR, Caplan LR, Come PC, Swinton Jr. NW, Breslin DJ. Cerebral emboli of paradoxical origin. Ann Neurol. 1983;13:314-319.
18. Kristensen B, Malm J, Carlberg B, Stegmayr B, Backman C, Fagerlund M, Olsson T. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden. Stroke. 1997;28: 1702-1709.
19. Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, Coste J, Mas JL. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Stroke. 2002;33:706-711.
20. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, Whisnant JP, Wiebers DO, Covalt JL, Petterson TM, Christianson TJ, Agmon Y. Patent foramen ovale: innocent or guilty? evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47: 440-445.
21. Ozdemir AO, Tamayo A, Munoz C, Dias B, Spence JD. Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism. J Neurol Sci. 2008;275:121-127.
22. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003;139: 753-760.
23. Messe SR, Silverman IE, Kizer JR, Homma S, Zahn C, Gronseth G, Kasner SE. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004; 62:1042-1050.
24. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113:e409-e449.
25. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams Jr. HP, Jackson CM, Pullicino P. Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
26. Dearani JA, Ugurlu BS, Danielson GK, Daly RC, McGregor CG, Mullany CJ, Puga FJ, Orszulak TA, Anderson BJ, Brown RD Jr, Schaff HV. Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events. Circulation. 1999; 100(suppl II):II-171-II-175.
27. Devuyst G, Ruchat P, Jeanrenaud X, Despland PA, Regli F, Aebischer N, Karpuz HM, Castillo V, Guffi M, Sadeghi H. Prognosis after stroke followed by surgical closure of patent foramen ovale: a prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology. 1996;47:1162-1166.
28. Homma S, Sacco RL, Sciacca RR, Smith C, Mohr JP. Surgical closure of patent foramen ovale in cryptogenic stroke patients. Stroke. 1997;28: 2376-2381.
29. Ruchat P, Bogousslavsky J, Hurni M, Fischer AP, Jeanrenaud X, von Segesser LK. Systematic surgical closure of patent foramen ovale in selected patients with cerebrovascular events due to paradoxical embolism: early results of a preliminary study. Eur J Cardiothorac Surg. 1997;11:824-827.
30. Homma S, Di Tullio MR, Sacco RL, Mihalatos D, Li Mandri G, Mohr JP. Characteristics of patent foramen ovale associated with cryptogenic stroke: a biplane transesophageal echocardiographic study. Stroke. 1994; 25:582-586.
31. Cujec B, Johnson DH. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol. 1999;15:57-64.
32. Hausmann D, Mügge A, Daniel WG. Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol. 1995;26: 1030-1038.
33. Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992;86:1902-1908.
34. Butera G, Bini MR, Chessa M, Bedogni F, Onofri M, Carminati M. Transcatheter closure of patent foramen ovale in patients with cryp-togenic stroke. Ital Heart J. 2001;2:115-118.
35. Chan KC, Godman MJ, Walsh K, Wilson N, Redington A, Gibbs JL. Transcatheter closure of atrial septal defect and interatrial communications with a new self expanding nitinol double disc device (Amplatzer septal occluder): multicentre UK experience. Heart. 1999;82:300-306.
36. Ende DJ, Chopra PS, Rao PS. Transcatheter closure of atrial septal defect or patent foramen ovale with the buttoned device for prevention of recurrence of paradoxic embolism. Am J Cardiol. 1996;78:233-236.
37. Sievert H, Babic UU, Hausdorf G, Schneider M, Höpp HW, Pfeiffer D, Pfisterer M, Friedli B, Urban P. Transcatheter closure of atrial septal defect and patent foramen ovale with ASDOS device (a multi-institutional European trial). Am J Cardiol. 1998;82:1405-1413.
38. Wahl A, Meier B, Haxel B, Nedeltchev K, Arnold M, Eicher E, Sturzenegger M, Seiler C, Mattle HP, Windecker S. Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology. 2001;57: 1330-1332. (Pubitemid 32947402)
39. Windecker S, Wahl A, Chatterjee T, Garachemani A, Eberli FR, Seiler C, Meier B. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation. 2000;101:893-898.
40. Easton JD, Saver JL, Albers GW. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40: 2276-2293.
41. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, Sherman DG. TIA Working Group. Transient ischemic attack: proposal for a new definition. N Engl J Med. 2002;347:1713-1716.
42. Kidwell CS, Alger JR, Di Salle F, Starkman S, Villablanca P, Bentson J, Saver JL. Diffusion MRI in patients with transient ischemic attacks. Stroke. 1999;30:1174, 2762-2763.
43. Brass L. Letter to FDA (unpublished). 2004.
44. Li G, Shih WJ, Xie T, Lu J. A sample size adjustment for clinical trials based on conditional power. Biostatistics. 2002;3:277-287.
45. Li G, Shih WJ, Wang Y. Two-stage adaptive design for clinical trials with survival data. J Biopharm Stat. 2005;15:707-718.